S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Yatsen Group Claims Record Scientific Presence at IFSCC Congress

With 20 research submissions accepted at the 36th IFSCC Congress in Perth, Yatsen Group has nearly doubled its previous year’s output at the global cosmetics forum. Selected from over 1,200 entries, the company’s work signals a widening influence in international beauty science and specialized clinical innovation.

Yatsen Group Claims Record Scientific Presence at IFSCC Congress
Photo: Bio & News

Jing Cheng, Chief Scientific Officer at Yatsen, noted that the record-breaking volume of presentations reflects the collaborative capacity of the group's global R&D ecosystem. The research covered nine distinct fields, ranging from skin neuroscience and computational toxicology to the complexities of the skin microbiome. These findings underpin the technical strategies of Yatsen’s portfolio, including brands like DR.WU, Galénic, Eve Lom, and Perfect Diary.

During the event, R&D Director Yi Deng introduced a novel microbiology testing methodology designed to reduce false negatives and improve accuracy in preservative interference detection. This focus on standard-setting follows years of aggressive investment; the company has funneled over RMB 770 million into research, maintaining an R&D spend exceeding 3% of revenue annually. By mid-2026, the group had secured 282 patent applications and 55 academic publications, anchoring its transition from a regional beauty player to an innovation-driven enterprise.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!